Carlos S. Moreno
PhD
Dr. Moreno's main research focus is in cancer bioinformatics and DNA microarray analysis of tumors; systems biology research of prostate, breast, and brain tumors to identify new drug targets and biomarkers.
Titles and Roles
- Associate Professor, Department of Pathology and Laboratory Medicine
- Emory University School of Medicine
- Associate Professor, Department of Biomedical Informatics
- Emory University School of Medicine
- Assistant Director for Education and Training
- Winship Cancer Institute of Emory University
- Research Program
- Cell and Molecular Biology
Biography
Carlos S. Moreno, PhD, is associate professor in the Departments of Pathology and Laboratory Medicine, and Biomedical Informatics at the Emory University School of Medicine. Dr. Moreno serves as assistant director for education and training and is a member of the Cell and Molecular Biology Research Program at Winship Cancer Institute of Emory University.
Dr. Moreno specializes in cancer bioinformatics and systems biology, analysis of genome-wide expression profiles, transcriptional networks, ChIP-chip studies, biological pathway analysis, and computational analysis of transcription factor binding sites. Dr. Moreno is project leader for informatics for the Emory Molecular Interaction Center for Functional genomics (MicFG) as part of the Cancer Target Discovery and Development (CTD²) Network to analyze TCGA data for protein-protein interaction networks.
Education
Dr. Moreno earned his BS and MS from Massachusetts Institute of Technology in Cambridge, Massachusetts. He received his PhD from Emory University in Atlanta, Georgia.
Research
Dr. Moreno's main research interests are in translational cancer bioinformatics and systems biology, to identify diagnostic markers for more effective and personalized therapies, to identify new potential therapeutic targets, and to better understand the biology of tumor progression. His research has focused on the dissection of the perturbed transcriptional networks in prostate, brain, breast, and ovarian cancers using DNA microarrays and next generation sequencing. His lab has identified several genes that are strongly correlated with prostate cancer progression, including two developmental transcription factors, HOXC6 and SOX4. His lab is also developing mRNA and microRNA biomarkers of recurrence in prostate cancer. His lab analyzes genome-wide expression profiles, transcriptional networks, ChIP-chip and ChIP-seq studies, biological pathways, and evolutionarily conserved transcription factor binding sites to dissect cancer-related transcriptional networks and identify new drug targets and biomarkers. They are heavily involved in analysis of data from The Cancer Genome Atlas project to identify potential drug targets as part of the Cancer Target Discovery and Development (CTD²) Network at NCI.
Publications
Publications Publication Date